Suchergebnisse - "Kaufman, Jonathan L"

PubPharm (21)

1

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

2

Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction

enthalten in: JCO oncology practice | 2023

von Sun, L. | Maples, K. | Hall, K. | +9

3

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma : extended follow-up of POLLUX, a randomized, open-label, phase 3 study

enthalten in: Leukemia | 2020

von Bahlis, N. | Dimopoulos, M. | White, D. | +16

4

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma : Utility of re-treatment with daratumumab among refractory patients

enthalten in: Cancer | 2019

von Nooka, A. | Joseph, N. | Kaufman, J. | +5

CommentIn: Cancer. 2019 Sep 1;125(17):2920-2922. - PMID 31090923

5

Registering a CD38 antibody upfront for multiple myeloma

enthalten in: Lancet (London, England) | 2019

von Hofmeister, C. | Nooka, A. | Kaufman, J. | +1

CommentOn: Lancet. 2019 Jul 6;394(10192):29-38. - PMID 31171419

6

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

enthalten in: Nature communications | 2019

von Barwick, B. | Neri, P. | Bahlis, N. | +11

7

Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents

enthalten in: Cancer | 2019

von Mina, R. | Joseph, N. | Kaufman, J. | +8

8

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma

enthalten in: Journal of oncology practice | 2018

von Chang, A. | Nasti, T. | Khan, M. | +6

9

Novel Approaches for the Management of AL Amyloidosis

enthalten in: Current hematologic malignancy reports | 2018

von Joseph, N. | Kaufman, J.

10

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

enthalten in: Blood | 2017

von Chari, A. | Suvannasankha, A. | Fay, J. | +13

CommentIn: Blood. 2017 Aug 24;130(8):957-958. - PMID 28838937